Drug Trial Radar · NCT05427383
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Last checked: Nov 19, 2026Latest source record: Dec 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
286
Planned (sponsor's estimate)
Start
Apr 7, 2022
Primary completion
Nov 2025
Study completion Nov 2026
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together. Randomized stage is designed to evaluate the OS and PFS in patients receiving KN026 and chemotherapy compared to patients receiving placebo and chemotherapy.
Conditions
- Stomach Cancer
Interventions
KN026/Placbo InjectionDrug
IV KN026/Placebo at 30 mg/kg on D1, Q3W
Paclitaxel InjectionDrug
IV Paclitaxel at 175 mg/m² on D1, Q3W
Docetaxel InjectionDrug
IV Docetaxel at 75 mg/m² on D1, Q3W
Irinotecan InjectionDrug
IV Irinotecan at 125 mg/m² on D1, D8, Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) according to RECIST 1.1 by IRCTime frame: Up to 2.5 years
- Overall Survival (OS) according to RECIST 1.1 by IRCTime frame: Up to 2.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.